Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

AbbVie reported for 3 months of 2023

4/27/23 ABBV

The Newmont Goldcorp announced a quarterly dividend

4/27/23 NEM

Altria Group reports 3 months of 2023

4/27/23 MO

Bristol-Myers Squibb reports 3 months of 2023

4/27/23 BMY

Comcast reported for 3 months of 2023

4/27/23 CMCSA

Newmont reported for 3 months of 2023

4/27/23 NEM

American Airlines reports 3 months of 2023

4/27/23 AAL

Eli Lilly has reported for 3 months of 2023

4/27/23 LLY

Honeywell International reports on 3 months of 2023

4/27/23 HON

Caterpillar reported 3 months of 2023

4/27/23 CAT